SCHEMBL5861386

SCHEMBL5861386

C[C@@H]1C[C@H]([C@H](Cc2ccccc2)NC(=O)OC(C)(C)C)OC1=O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ATM Q13315 1/20 0.48
CTSS P25774 2/20 0.47
CTSL P07711 1/20 0.47
CTSB P07858 1/20 0.47
CTSK P43235 1/20 0.47
ACE P12821 2/20 0.45
KLK5 Q9Y337 2/20 0.44
AKT1 P31749 1/20 0.44
ALDH1A1 P00352 2/20 0.43
APP P05067 2/20 0.43
MEN1 O00255 1/20 0.42
LMNA P02545 1/20 0.42
PKM P14618 1/20 0.42
HPGD P15428 1/20 0.42
ALOX15 P16050 1/20 0.42
TSHR P16473 1/20 0.42
XBP1 P17861 1/20 0.42
HTT P42858 1/20 0.42
KMT2A Q03164 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3539282 1.00 ATM (0.48) ATMCTSSCTSLCTSBCTSK
SCHEMBL5620017 1.00 ATM (0.48) ATMCTSSCTSLCTSBCTSK
SCHEMBL4042099 1.00 ATM (0.48) ATMCTSSCTSLCTSBCTSK
SCHEMBL4042106 1.00 ATM (0.48) ATMCTSSCTSLCTSBCTSK
SCHEMBL5620023 1.00 ATM (0.48) ATMCTSSCTSLCTSBCTSK
SCHEMBL9296151 0.90 ATM (0.47) ATMCTSSCTSLCTSBCTSK
SCHEMBL3800004 0.89 ATM (0.47) ATMCTSSCTSLCTSBCTSK
SCHEMBL4881213 0.89 CTSS (0.39) ATMCTSSCTSLCTSBCTSK
SCHEMBL4881219 0.89 CTSS (0.39) ATMCTSSCTSLCTSBCTSK
SCHEMBL6312228 0.88 ATM (0.46) ATMCTSSCTSLCTSBCTSK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7132568-B2 Aspartyl protease inhibitors SUNESIS PHARMACEUTICALS, INC. (US) 2006-11-07 US disclosed
US-20040132782-A1 Aspartyl protease inhibitors SUNESIS PHARMACEUTICALS, INC. 2004-07-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040132782-A1 Aspartyl protease inhibitors BACE1, APP, BACE2 ATM 3804/4885CTSS 59/4885CTSL 69/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.